ACADIA Pharmaceuticals Inc (ACAD) - Total Assets
Based on the latest financial reports, ACADIA Pharmaceuticals Inc (ACAD) holds total assets worth $1.61 Billion USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore ACAD operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
ACADIA Pharmaceuticals Inc - Total Assets Trend (2000–2025)
This chart illustrates how ACADIA Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. See ACAD book value for net asset value and shareholders' equity analysis.
ACADIA Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
ACADIA Pharmaceuticals Inc's total assets of $1.61 Billion consist of 67.9% current assets and 32.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 11.4% |
| Accounts Receivable | $148.23 Million | 9.5% |
| Inventory | $34.67 Million | 2.2% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $108.89 Million | 7.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2000–2025)
This chart illustrates how ACADIA Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see ACAD market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ACADIA Pharmaceuticals Inc's current assets represent 67.9% of total assets in 2025, an increase from 0.0% in 2000.
- Cash Position: Cash and equivalents constituted 11.4% of total assets in 2025, up from 0.0% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, an increase from 0.0% in 2000.
- Asset Diversification: The largest asset category is accounts receivable at 9.5% of total assets.
ACADIA Pharmaceuticals Inc Competitors by Total Assets
Key competitors of ACADIA Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.82 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068
|
China | CN¥3.21 Billion |
ACADIA Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.59 | 2.88 | 6.77 |
| Quick Ratio | 3.48 | 2.80 | 6.66 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $790.49 Million | $568.41 Million | $550.40 Million |
ACADIA Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between ACADIA Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.93 |
| Latest Market Cap to Assets Ratio | 2.34 |
| Asset Growth Rate (YoY) | 31.7% |
| Total Assets | $1.56 Billion |
| Market Capitalization | $3.66 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values ACADIA Pharmaceuticals Inc's assets at a significant premium (2.34x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: ACADIA Pharmaceuticals Inc's assets grew by 31.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for ACADIA Pharmaceuticals Inc (2000–2025)
The table below shows the annual total assets of ACADIA Pharmaceuticals Inc from 2000 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $1.56 Billion | +31.69% |
| 2024-12-31 | $1.19 Billion | +58.59% |
| 2023-12-31 | $748.96 Million | +27.41% |
| 2022-12-31 | $587.81 Million | -16.04% |
| 2021-12-31 | $700.12 Million | -10.54% |
| 2020-12-31 | $782.62 Million | -0.07% |
| 2019-12-31 | $783.18 Million | +44.98% |
| 2018-12-31 | $540.20 Million | +40.49% |
| 2017-12-31 | $384.51 Million | -31.48% |
| 2016-12-31 | $561.15 Million | +152.89% |
| 2015-12-31 | $221.90 Million | -31.82% |
| 2014-12-31 | $325.46 Million | +72.09% |
| 2013-12-31 | $189.12 Million | +74.16% |
| 2012-12-31 | $108.59 Million | +238.14% |
| 2011-12-31 | $32.11 Million | -16.36% |
| 2010-12-31 | $38.39 Million | -22.72% |
| 2009-12-31 | $49.68 Million | -23.19% |
| 2008-12-31 | $64.68 Million | -51.94% |
| 2007-12-31 | $134.58 Million | +50.30% |
| 2006-12-31 | $89.54 Million | +43.26% |
| 2005-12-31 | $62.51 Million | +54.85% |
| 2004-12-31 | $40.37 Million | +27.36% |
| 2003-12-31 | $31.69 Million | +97.79% |
| 2002-12-31 | $16.02 Million | -27.03% |
| 2001-12-31 | $21.96 Million | -35.63% |
| 2000-12-31 | $34.11 Million | -- |
About ACADIA Pharmaceuticals Inc
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog … Read more